Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis

Table 1 Baseline characteristics of included studies for meta-analysis

First author, year	Country	Race	Sample size	Sex		Gene polymorphism	Outcome indicators	Classification criteria	NOS score
First author, year	Country	Race	Sample size	Male	Female	Gene polymorphism	Outcome indicators	Classification criteria	NOS score
Hattinger CM, 2016 [24]	Italy	Caucasian	57	37	20	α, β	ε, ι, ζ, η	CTCAE	8
Ren HY, 2011 [14, 25]	China	Asian	210	109	101	γ	ε, θ, ι, η	WHO	8
Windsor RE, 2012 [26]	United Kingdom	Caucasian	58	34	24	α, β	ε, θ	CTCAE	7
Jabeen S, 2015 [27]	Norway	Caucasian	62	-	-	γ, α, δ	θ, ζ	CTCAE	7
Park JA, 2016 [28]	Korea	Asian	37	21	17	γ, α, δ	θ, ζ, η	CTCAE	6
Goricar K, 2014 [29]	Slovenia	Caucasian	74	38	36	β, δ	ε, ζ	CTCAE	6
Xu L, 2018 [30]	China	Asian	109	58	51	γ	θ, ζ, η, ε	CTCAE	8
Lambrecht L, 2017 [15]	Belgium	Caucasian	48	23	25	γ	θ, ζ, η, ε	CTCAE	6
Wei Y, 2022 [31]	China	Asian	39	24	15	γ	θ, ζ, η, ι	CTCAE	9
Zhou XK, 2013 [32]	China	Asian	40	23	17	γ, α	θ, ζ, η, ι, ε	CTCAE	7
Hegyi M, 2017 [33]	Hungarian	Caucasian	59	-	-	δ, β	ε, ζ	CTCAE	7
Patino-Garcia A, 2009 [34]	Spain	Caucasian	96	41	55	γ, α, δ	ε, η, ι	WHO	9

α MTHFR A1298C, β MDR1 C3435T; γ MTHFR C677T; δ RFC1 G80A, ε Hematotoxicity, ζ Hepatotoxicity, η Nephrotoxicity, θ Mucositis, ι Gastrointestinal toxicity, CTCAE Common terminology criteria for adverse events, WHO World Health Organization

ISSN: 1477-7819